,tid,pref_name,lig_chemblid,aid,outcome,title
303,CHEMBL220,Acetylcholinesterase,CHEMBL322343,272365,Active,inhibition of bovine erythrocyte ache
302,CHEMBL220,Acetylcholinesterase,CHEMBL322343,243153,Active,in vitro inhibitory activity against bovine acetylcholinesterase
301,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30692,Active,inhibition of acetylcholinesterase  ache activity in bovine erythrocytes
234,CHEMBL220,Acetylcholinesterase,CHEMBL3958499,1330795,Active,inhibition of electric eel ache using acetylthiocholine iodide as substrate incubated for 5 mins followed by substrate addition measured for 1 min by ellman's method
300,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30692,Active,inhibition of acetylcholinesterase  ache activity in bovine erythrocytes
299,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30682,Active,compound was evaluated for the inhibition of acetylcholinesterase of bovine erythrocytes
142,CHEMBL4822,Beta-secretase 1,CHEMBL3938461,1344819,Active,time resolved endpoint proteolysis assay: inhibitor compounds prepared at 3 xd7 the desired final concentration in 1 xd7 bace assay buffer  20 mm sodium acetate ph 5 0 10% glycerol 0 1% brij 35 supplemented with 7 5% dmso are pre incubated with an equal volume of autobace 2 enzyme diluted in 1 xd7 bace assay buffer  final enzyme concentration 1 nm in black 384 well nunc plates for 30 minutes at 30 xb0 c the assay is initiated by addition of an equal volume of the qsy7 eisevnldaefc eu amide substrate  200 nm final concentration km8  x3bc m for 4  x3bc m for autobace 2 prepared in 1 xd7 bace assay buffer supplemented with 7 5% dmso and incubated for 90 minutes at 30 xb0 c dmso is present at 5% final concentration in the assay following laser excitation of sample wells at 320 nm the fluorescence signal at 620 nm is collected for 400 ms following a 50  x3bc s delay on a rubystar htrf plate reader  bmg labtechnologies 
341,CHEMBL4822,Beta-secretase 1,CHEMBL3670929,1257989,Active,immunofluorescence resonance energy transfer  fret assay: the fret assay was performed essentially as described in gruninger leitch et al journal of biological chemistry  2002 277 7 4687 93  substrate and inhibitor profile of bace  beta secretase and comparison with other mammalian aspartic proteases in summary a peptide is designed that is cleaved by the protease the peptide is labelled with dabcyl at the n terminus and lucifer yellow at the c terminus such that for an intact peptide the lucifer yellow fluorescence is quenched by the dabcyl when the peptide is cut by bace2 the quenching is removed and a fluorescent signal is generated the assay was performed as described in grueninger et al 2002 at ph 4 5 using a substrate concentration of 5  x3bc m a fret peptide based on the tmem27 sequence was devised dabcyl qtleflkips lucy  seq id no: 1 bace2 had a high activity against this sequence which is unrelated to the known app based substrates conversely bace1 had i
342,CHEMBL4822,Beta-secretase 1,CHEMBL3670929,1257990,Active,immunofluorescence resonance energy transfer  fret assay: the fret assay was performed essentially as described in gruninger leitch et al journal of biological chemistry  2002 277 7 4687 93  substrate and inhibitor profile of bace  beta secretase and comparison with other mammalian aspartic proteases in summary a peptide is designed that is cleaved by the protease the peptide is labelled with dabcyl at the n terminus and lucifer yellow at the c terminus such that for an intact peptide the lucifer yellow fluorescence is quenched by the dabcyl when the peptide is cut by bace2 the quenching is removed and a fluorescent signal is generated the assay was performed as described in grueninger et al 2002 at ph 4 5 using a substrate concentration of 5  x3bc m a fret peptide based on the tmem27 sequence was devised dabcyl qtleflkips lucy  seq id no: 1 bace2 had a high activity against this sequence which is unrelated to the known app based substrates conversely bace1 had i
106,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,367820,Active,inhibition of human recombinant ca1 by stopped flow co2 hydrase assay
326,CHEMBL261,Carbonic anhydrase I,CHEMBL215917,271037,Active,inhibition of human cloned ca1 by co2 hydration assay
69,CHEMBL261,Carbonic anhydrase I,CHEMBL1242794,512001,Active,inhibition of human cloned ca1 after 15 mins by stopped flow co2 hydration assay
71,CHEMBL261,Carbonic anhydrase I,CHEMBL2070210,678515,Active,inhibition of human ca1 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique
77,CHEMBL261,Carbonic anhydrase I,CHEMBL2148105,687196,Active,inhibition of human recombinant cytosolic ca1 preincubated for 15 mins by stopped flow co2 hydration method
199,CHEMBL261,Carbonic anhydrase I,CHEMBL387402,670598,Inactive,neuroprotective activity in wistar rat acute hippocampal ca1 region assessed as protection from oxygen glucose deprivation induced anoxia depolarization at 1 um administered 15 mins before and during 7 mins oxygen deprivation challenge
89,CHEMBL261,Carbonic anhydrase I,CHEMBL232816,295289,Active,inhibition of human recombinant ca1 after 15 mins by co2 hydration stopped flow assay
200,CHEMBL261,Carbonic anhydrase I,CHEMBL387402,670600,Active,neuroprotective activity in wistar rat hippocampal ca1 region assessed as change in field excitatory postsynaptic potential at basal conditions at 1 to 5 um by electrophysiological analysis
224,CHEMBL261,Carbonic anhydrase I,CHEMBL2326509,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method
114,CHEMBL261,Carbonic anhydrase I,CHEMBL196871,47710,Active,inhibition of human recombinant carbonic anhydrase i  ca1 
109,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,552127,Active,inhibition of human recombinant ca1 by stopped flow co2 hydration assay
275,CHEMBL261,Carbonic anhydrase I,CHEMBL2321923,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method
108,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,459696,Active,inhibition of brucella suis ca1 expressed in escherichia coli bl21 de3 by stopped flow co2 hydration assay
103,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 
104,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
105,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,263636,Active,inhibition of human recombinant ca1
107,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,436563,Active,inhibition of human recombinant ca1 by stopped flow co2 assay
102,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,47713,Active,inhibition of human carbonic anhydrase i  cai 
0,CHEMBL261,Carbonic anhydrase I,CHEMBL2326507,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method
2,CHEMBL261,Carbonic anhydrase I,CHEMBL215355,271037,Active,inhibition of human cloned ca1 by co2 hydration assay
19,CHEMBL261,Carbonic anhydrase I,CHEMBL2326506,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method
17,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,239250,Active,inhibitory activity against beta carbonic anhydrase  cab from methanobacterium thermoautotrophicum
16,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
15,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 
12,CHEMBL261,Carbonic anhydrase I,CHEMBL215276,271037,Active,inhibition of human cloned ca1 by co2 hydration assay
14,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,47713,Active,inhibition of human carbonic anhydrase i  cai 
79,CHEMBL205,Carbonic anhydrase II,CHEMBL2326509,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method
85,CHEMBL205,Carbonic anhydrase II,CHEMBL2326508,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method
86,CHEMBL205,Carbonic anhydrase II,CHEMBL2326508,727275,Active,inhibition of human ca2 ala65ser and asn67gln double mutant expressed in escherichia coli strain bl21  de3 after 6 hrs by stopped flow co2 hydration method
20,CHEMBL205,Carbonic anhydrase II,CHEMBL1200739,552128,Active,inhibition of human recombinant ca2 by stopped flow co2 hydration assay
54,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,1461934,Active,inhibition of human ca2 incubated for 15 mins by stopped flow co2 hydration assay
53,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,1235241,Active,inhibition of human ca2 after 15 mins by stopped flow/co2 hydration assay
52,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,758952,Active,inhibition of human recombinant ca2 by co2 hydration assay
51,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,724721,Active,inhibition of human recombinant wild type ca2 by stopped flow co2 hydration method
359,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,724721,Active,inhibition of human recombinant wild type ca2 by stopped flow co2 hydration method
355,CHEMBL205,Carbonic anhydrase II,CHEMBL2321923,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method
360,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,758952,Active,inhibition of human recombinant ca2 by co2 hydration assay
198,CHEMBL205,Carbonic anhydrase II,CHEMBL234507,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
21,CHEMBL205,Carbonic anhydrase II,CHEMBL1200739,1262264,Active,inhibition of human ca2 incubated for 15 mins prior to testing by stopped flow co2 hydrase assay
119,CHEMBL205,Carbonic anhydrase II,CHEMBL442798,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
249,CHEMBL205,Carbonic anhydrase II,CHEMBL395543,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
256,CHEMBL205,Carbonic anhydrase II,CHEMBL394355,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
362,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,1461934,Active,inhibition of human ca2 incubated for 15 mins by stopped flow co2 hydration assay
7,CHEMBL205,Carbonic anhydrase II,CHEMBL2326507,727275,Active,inhibition of human ca2 ala65ser and asn67gln double mutant expressed in escherichia coli strain bl21  de3 after 6 hrs by stopped flow co2 hydration method
361,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,1235241,Active,inhibition of human ca2 after 15 mins by stopped flow/co2 hydration assay
6,CHEMBL205,Carbonic anhydrase II,CHEMBL2326507,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method
254,CHEMBL3594,Carbonic anhydrase IX,CHEMBL521690,352789,Active,inhibition of human ca9 catalytic domain by co2 hydration stopped flow assay
206,CHEMBL3594,Carbonic anhydrase IX,CHEMBL3798303,1295838,Active,slow rate dissociation at human recombinant ca9 catalytic domain after 30 sec by surface plasmon resonance assay
205,CHEMBL3594,Carbonic anhydrase IX,CHEMBL3798303,1295826,Active,binding affinity to human recombinant ca9 catalytic domain by fluorescence based thermal shift assay
306,CHEMBL3242,Carbonic anhydrase XII,CHEMBL2070209,678518,Active,inhibition of human ca12 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique
188,CHEMBL3242,Carbonic anhydrase XII,CHEMBL2323124,725593,Active,inhibition of human ca12 by stopped flow assay
282,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL50,298693,Active,inhibition of cdk2
337,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL535,479518,Inactive,inhibition of cdk2
336,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL535,256632,Inactive,average binding constant for cdk2 nanot active at 10 um
63,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL226471,288462,Active,inhibition of cdk2
267,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL502835,624844,Active,binding constant for cdk2 kinase domain
82,CHEMBL2722,Cytochrome P450 11B2,CHEMBL1440486,1344534,Active,cellular inhibition assay: v79mz cells expressing human cyp11b1 and human cyp11b2 genes respectively were grown on 24 well cell culture plates  8 xd7 10^5 cells per well with 1 9 cm^2 culture area per well in 1 ml dmem culture medium until confluence before testing the dmem culture medium was removed and 450  x3bc l of fresh dmem containing the inhibitor in at least three different concentrations for determining the ic50 value was added to each well every value was determined at least three times after a pre incubation step of 60 min at 37 xb0 c the reaction was started by the addition of 50  x3bc l of dmem containing the substrate 11 deoxycorticosterone  containing 0 15  x3bc ci of [1 2 3h] 11 deoxycorticosterone dissolved in ethanol final concentration 100 nm the v79mzh11b1 cells were incubated for 25 min the v79mzh11b2 cells were incubated for 50 min controls were treated in the same way without inhibitors the maximum dmso concentration in each well was 1% e
286,CHEMBL238,Dopamine transporter,CHEMBL257593,331704,Active,inhibition of [3h]da uptake at human recombinant dat expressed in hek293 cells
120,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3916828,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
322,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
323,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
324,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
65,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
325,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
330,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
368,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa
329,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
328,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
64,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
352,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3959516,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
66,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
331,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
371,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa
67,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
370,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa
369,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa
31,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344881,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
30,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
125,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3401361,1193339,Active,inhibition of fgfr1  unknown origin after 90 mins by tr fret assay
29,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
194,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3933000,1340075,Active,inhibition of fgfr1  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay
32,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344882,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
44,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL553,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um
304,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3913492,1340075,Active,inhibition of fgfr1  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay
385,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL31965,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um
309,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3941999,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
225,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL103667,256654,Inactive,average binding constant for fgfr2 nanot active at 10 um
226,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL103667,636437,Active,inhibition of fgfr2
307,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
308,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
24,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3401368,1193341,Active,inhibition of fgfr3  unknown origin after 90 mins by tr fret assay
10,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3787112,1291012,Active,inhibition of fgfr3 k650e mutant  unknown origin in presence of [gamma33p]atp
11,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3948944,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
111,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL103667,256624,Inactive,average binding constant for fgfr3 nanot active at 10 um
274,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3401364,1193341,Active,inhibition of fgfr3  unknown origin after 90 mins by tr fret assay
41,CHEMBL325,Histone deacetylase 1,CHEMBL564916,434540,Active,inhibition of human hdac1 by fluorimetry
314,CHEMBL325,Histone deacetylase 1,CHEMBL3110015,1065629,Active,inhibition of human recombinant full length hdac1 using  ac arg gly lys ac as substrate after 60 mins by fluorescence assay
49,CHEMBL325,Histone deacetylase 1,CHEMBL3981567,1343401,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
315,CHEMBL325,Histone deacetylase 1,CHEMBL3110015,1293433,Active,inhibition of hdac1  unknown origin using boc lys ac  amc as substrate
196,CHEMBL325,Histone deacetylase 1,CHEMBL3338404,1164906,Active,inhibition of hdac1  unknown origin using fluorogenic peptide as substrate by fluorescence assay
36,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343397,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
37,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343401,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
48,CHEMBL325,Histone deacetylase 1,CHEMBL3981567,1343397,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
38,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343403,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
39,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343405,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
40,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343406,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
395,CHEMBL325,Histone deacetylase 1,CHEMBL2337867,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control
50,CHEMBL325,Histone deacetylase 1,CHEMBL3981567,1343403,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
273,CHEMBL325,Histone deacetylase 1,CHEMBL3589699,1233250,Inactive,inhibition of human recombinant hdac1 after 15 mins by fluorogenic assay
312,CHEMBL325,Histone deacetylase 1,CHEMBL2046613,670970,Active,inhibition of human recombinant his6 tagged and gst fuses hdac1 expressed in insect high5 cells using ac lys tyr lys e acetyl  amc as substrate after 24 hrs by fluorescence assay
292,CHEMBL1829,Histone deacetylase 3,CHEMBL4063938,1469176,Active,inhibition of hdac3 in human mv4 11 cells assessed as increase in acetylated histone h4 level at 0 25 to 2 um after 24 hrs by western blot analysis
291,CHEMBL1829,Histone deacetylase 3,CHEMBL4063938,1469173,Active,inhibition of hdac3 in human mv4 11 cells assessed as increase in acetylated histone h3 level at 0 25 to 2 um after 24 hrs by western blot analysis
364,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469138,Active,downregulation of hdac6 protein expression in human mv4 11 cells at > 0 5 um after 24 hrs by western blot analysis
367,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469192,Inactive,inhibition of hdac6 in human pc3 cells assessed as increase in acetylated tubulin level at 1 to 2 um after 24 hrs by western blot method
402,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420642,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 24 hrs by western blot
400,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420640,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 24 hrs by western blot
393,CHEMBL1865,Histone deacetylase 6,CHEMBL1934896,637889,Active,inhibition of recombinant human hdac6 using boc l lys acetyl  mca as substrate by fluorogenic enzymatic assay
401,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420641,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 48 hrs by western blot
399,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420635,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 4 hrs by western blot
398,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420634,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 4 hrs by western blot
394,CHEMBL1865,Histone deacetylase 6,CHEMBL1934896,1439777,Active,inhibition of human hdac6 using boc lys ac  amc as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin based fluorescence assay
365,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469177,Active,inhibition of hdac6 in human mv4 11 cells assessed as increase in acetylated tubulin level at 0 25 to 2 um after 24 hrs by western blot analysis
366,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469191,Inactive,downregulation of hdac6 protein expression in human pc3 cells at 1 to 2 um after 24 hrs by western blot method
403,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420643,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 48 hrs by western blot
130,CHEMBL1865,Histone deacetylase 6,CHEMBL2170019,700671,Inactive,inhibition of hdac6 in human jurkat cells assessed as increase of acetylated alpha tubulin level at 2 to 20 um after 24 hrs by western blot analysis
62,CHEMBL4204,MAP kinase signal-integrating kinase 2,CHEMBL101253,256576,Inactive,average binding constant for mknk2 nanot active at 10 um
129,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345548,Active,human fms related tyrosine kinase 1  type iv rtks: vegf  vascular endothelial growth factor receptor family 
128,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345520,Active,human fms related tyrosine kinase 4  type iv rtks: vegf  vascular endothelial growth factor receptor family 
127,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family 
231,CHEMBL280,Matrix metalloproteinase 13,CHEMBL460899,346594,Active,inhibition of human recombinant mmp13
218,CHEMBL280,Matrix metalloproteinase 13,CHEMBL1801052,604454,Active,inhibition of human mmp13 assessed as cleavage of fluorogenic peptide mcapro leu gly leu dpa ala arg nh2 by fluorometric assay
3,CHEMBL321,Matrix metalloproteinase 9,CHEMBL43147,310906,Active,inhibition of mmp9
313,CHEMBL321,Matrix metalloproteinase 9,CHEMBL104022,259187,Active,binding affinity to mmp9
100,CHEMBL332,Matrix metalloproteinase-1,CHEMBL561036,419737,Active,inhibition of mmp1
230,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259202,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
229,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259201,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
228,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259200,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
227,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259199,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
55,CHEMBL332,Matrix metalloproteinase-1,CHEMBL550548,419737,Active,inhibition of mmp1
56,CHEMBL332,Matrix metalloproteinase-1,CHEMBL550548,419746,Active,inhibition of mmp1 mediated collagen degradation by sds page
233,CHEMBL332,Matrix metalloproteinase-1,CHEMBL1795351,603756,Active,inhibition of human mmp1 by fluorometric assay
384,CHEMBL332,Matrix metalloproteinase-1,CHEMBL573935,440425,Active,inhibition of para aminophenylmercuric acetate activated human pro mmp1 after 4 hrs by fluorimetry
18,CHEMBL332,Matrix metalloproteinase-1,CHEMBL127867,108894,Active,inhibitory activity against matrix metalloprotease 1  mmp1 
347,CHEMBL332,Matrix metalloproteinase-1,CHEMBL445971,349395,Inactive,inhibition of mmp1 up to 25 um
4,CHEMBL333,Matrix metalloproteinase-2,CHEMBL348335,107154,Active,inhibitory activity against human gelatinase a  matrix metalloprotease 2 mmp2 
253,CHEMBL333,Matrix metalloproteinase-2,CHEMBL98917,310905,Active,inhibition of mmp2
45,CHEMBL333,Matrix metalloproteinase-2,CHEMBL1801052,604449,Active,inhibition of human mmp2 assessed as cleavage of fluorogenic peptide mcapro leu gly leu dpa ala arg nh2 by fluorometric assay
240,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
241,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
242,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
243,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504905,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
247,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588411,Active,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprd1 homodimerization
245,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
246,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588408,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput dose response assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
237,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
248,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588435,Inactive,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprm1 homodimerization
235,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
244,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
236,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
238,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
239,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
13,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL24828,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um
250,CHEMBL222,Norepinephrine transporter,CHEMBL115710,145866,Active,displacement of [3h]nisoxetine from norepinephrine transporter  net of rat brain
353,CHEMBL222,Norepinephrine transporter,CHEMBL476108,342786,Active,binding affinity to rat net
9,CHEMBL222,Norepinephrine transporter,CHEMBL4074774,1472455,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting method
8,CHEMBL222,Norepinephrine transporter,CHEMBL4074774,1472455,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting method
1,CHEMBL222,Norepinephrine transporter,CHEMBL3126751,1075730,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting analysis
222,CHEMBL222,Norepinephrine transporter,CHEMBL3331501,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay
338,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,434989,Inactive,fluorescence based cell based primary high throughput screening assay to identify antagonists of the orexin 1 receptor  ox1r hcrtr1 
339,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,463079,Inactive,fluorescence based counterscreen for orexin 1 receptor  ox1r antagonists: cell based assay to identify antagonists of the parental cho cell line
340,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,485270,Inactive,fret based cell based primary high throughput screening assay to identify antagonists of the orexin 1 receptor  ox1r hcrtr1 
283,CHEMBL5113,Orexin receptor 1,CHEMBL3672939,1258840,Active,flipr ca2+ flux assay: the utility of the compounds in accordance with the present invention as orexin receptor ox1r and/or ox2r antagonists may be readily determined without undue experimentation by methodology well known in the art including the flipr ca2+ flux assay  okumura et al biochem biophys res comm 280:976 981 2001 in a typical experiment the ox1 and ox2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the following experimental method for intracellular calcium measurements chinese hamster ovary  cho cells expressing the rat orexin 1 receptor or the human orexin 2 receptor are grown in iscove's modified dmem containing 2 mm l glutamine 0 5 g/ml g418 1% hypoxanthine thymidine supplement 100 u/ml penicillin 100 ug/ml streptomycin and 10% heat inactivated fetal calf serum  fcs the cells are seeded at 20 000 cells/well into becton dickinson black 384 well clear bottom sterile plates coated with poly d l
210,CHEMBL4792,Orexin receptor 2,CHEMBL1463349,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
124,CHEMBL4792,Orexin receptor 2,CHEMBL1502109,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
123,CHEMBL4792,Orexin receptor 2,CHEMBL1502109,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
201,CHEMBL4792,Orexin receptor 2,CHEMBL1559065,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
259,CHEMBL4792,Orexin receptor 2,CHEMBL1418004,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
389,CHEMBL4792,Orexin receptor 2,CHEMBL1327720,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
388,CHEMBL4792,Orexin receptor 2,CHEMBL1327720,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
380,CHEMBL4792,Orexin receptor 2,CHEMBL1301892,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
379,CHEMBL4792,Orexin receptor 2,CHEMBL1301892,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
80,CHEMBL4792,Orexin receptor 2,CHEMBL1576843,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
81,CHEMBL4792,Orexin receptor 2,CHEMBL1576843,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
297,CHEMBL4792,Orexin receptor 2,CHEMBL1379934,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
258,CHEMBL4792,Orexin receptor 2,CHEMBL1418004,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
296,CHEMBL4792,Orexin receptor 2,CHEMBL1379934,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
293,CHEMBL4792,Orexin receptor 2,CHEMBL1518032,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
285,CHEMBL4792,Orexin receptor 2,CHEMBL1501678,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
284,CHEMBL4792,Orexin receptor 2,CHEMBL1501678,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
202,CHEMBL4792,Orexin receptor 2,CHEMBL1559065,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
294,CHEMBL4792,Orexin receptor 2,CHEMBL1518032,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
209,CHEMBL4792,Orexin receptor 2,CHEMBL1463349,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
95,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589377,1233493,Active,inhibition of gst tagged bovine p110alpha expressed in sf9/baculovirus system using [gamma 33p]atp by scintillation proximity assay
96,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589377,1233502,Active,cytotoxic activity against human hela cells over expressing pi3k p110alpha incubated for 72 hrs by srb assay
97,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589377,1233503,Active,cytotoxic activity against human skov3 cells expressing pik3ca mutant incubated for 72 hrs by srb assay
268,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4071083,1482747,Active,antiproliferative activity against human skov3 cells harboring pik3ca mutant after 72 hrs by cck 8 assay
377,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646594,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
58,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2326965,729013,Active,inhibition of pi3k p110delta  unknown origin 
378,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646594,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
115,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3589376,1233495,Active,inhibition of his tagged p110gamma  unknown origin expressed in sf9/baculovirus system using [gamma 33p]atp by scintillation proximity assay
257,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3112866,1068548,Active,inhibition of c terminal ploy his tagged human pi3kgamma expressed in baculovirus infected sf9 cells using pi 4 5 p2 as substrate after 15 mins by htrf assay
215,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156617,Active,maximum transcriptional activation of human ppar delta receptor
216,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156625,Active,binding affinity for human ppar delta receptor
217,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156945,Active,maximum transcriptional activation of human ppar gamma receptor
34,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL394849,291758,Active,displacement of [3h]rosiglitazone from ppar gamma
214,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156148,Inactive,maximum transcriptional activation of human ppar alpha receptor iainactive
5,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL393805,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba
327,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL239563,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba
350,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL360992,246429,Inactive,agonist activity against human ppargamma in cos 1 cell gal4 assay na not active  less than 20% activation at 10 um 
232,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL1725279,256661,Inactive,average binding constant for pdgfrb nanot active at 10 um
59,CHEMBL2973,Rho-associated protein kinase 2,CHEMBL502835,397087,Inactive,inhibition of human rock2 at 10 umol/l
42,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387471,749894,Active,cytotoxicity against mouse ba/f3 cells overexpressing pim1 after 18 hrs by celltitre glo assay
43,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387471,749898,Active,inhibition of pim1  unknown origin using fam pimtide as substrate after 90 mins by spectrophotometry in presence of atp
118,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL496996,410272,Active,inhibition of human recombinant pim1 by atp depletion assay
332,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL3794146,1293772,Active,inhibition of pim1  unknown origin using bad peptide preincubated for 15 mins followed by atp addition measured after 60 to 100 mins by kinase glo reagent based luminescence assay
61,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL3792742,1293772,Active,inhibition of pim1  unknown origin using bad peptide preincubated for 15 mins followed by atp addition measured after 60 to 100 mins by kinase glo reagent based luminescence assay
25,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1910907,626549,Active,inhibition of pim1 using bad peptide as substrate preincubated for 15 mins measured after 60 to 100 mins by luminescence assay
75,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387465,749898,Active,inhibition of pim1  unknown origin using fam pimtide as substrate after 90 mins by spectrophotometry in presence of atp
74,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387465,749894,Active,cytotoxicity against mouse ba/f3 cells overexpressing pim1 after 18 hrs by celltitre glo assay
70,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL494355,418377,Active,inhibition of pim1 in presence of 1 um atp
68,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL535,256650,Inactive,average binding constant for pim1 nanot active at 10 um
60,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1910912,626549,Active,inhibition of pim1 using bad peptide as substrate preincubated for 15 mins measured after 60 to 100 mins by luminescence assay
90,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL496587,410272,Active,inhibition of human recombinant pim1 by atp depletion assay
26,CHEMBL4523,Serine/threonine-protein kinase PIM2,CHEMBL939,256570,Inactive,average binding constant for pim2 nanot active at 10 um
381,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL234006,292746,Active,displacement of [3h]ketanserin from 5ht2a receptor expressed in hek293 cells
382,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL234006,292752,Inactive,agonist activity at 5ht2a receptor expressed in hek293 cells assessed as intracellular calcium mobilisation up to 10 um
305,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL490632,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser
84,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL402143,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser
83,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL402143,320831,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells
57,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL515472,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser
376,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL964,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a 
207,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL489408,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser
354,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL440687,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a 
195,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL492917,418828,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux by flipr assay
349,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL476839,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser
383,CHEMBL228,Serotonin transporter,CHEMBL3084884,273269,Active,displacement of [3h]citalopram from sert in sprague dawley rat brain
46,CHEMBL228,Serotonin transporter,CHEMBL559490,431883,Active,inhibition of [3h]hydroxytryptamine creatinine sulfate uptake at human sert expressed in human jar cells
203,CHEMBL228,Serotonin transporter,CHEMBL2064645,1443748,Inactive,enhancing of [125i]rti 55 binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
321,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
320,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
319,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
318,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259103,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
204,CHEMBL228,Serotonin transporter,CHEMBL2064645,1443749,Inactive,enhancing of [3h]mazindol binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
78,CHEMBL228,Serotonin transporter,CHEMBL566886,459713,Active,inhibition of [3h]serotonin uptake at human sert expressed in hek293 cells
351,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL518292,485,Inactive,primary hts assay for s1p3 antagonists
157,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435644,Active,binding constant for abl1 e255k kinase domain
146,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256665,Active,average binding constant for abl1 nanot active at 10 um
167,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624984,Active,binding constant for abl1 h396p  phosphorylated kinase domain
166,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624983,Active,binding constant for abl1 h396p  non phosphorylated kinase domain
182,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1350953,Active,inhibition of abl1  unknown origin 
164,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624981,Active,binding constant for abl1 f317l  non phosphorylated kinase domain
163,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624980,Active,binding constant for abl1 f317i  phosphorylated kinase domain
162,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624979,Active,binding constant for abl1 f317i  non phosphorylated kinase domain
161,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624978,Active,binding constant for abl1 e255k  phosphorylated kinase domain
160,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435897,Active,binding constant for abl1 t315i kinase domain
159,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435776,Active,binding constant for abl1 y253f kinase domain
158,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435775,Active,binding constant for abl1 kinase domain
148,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256667,Active,average binding constant for abl1 e255k nanot active at 10 um
145,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,240823,Active,inhibition of c abl tyrosine kinase activity
144,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,228824,Active,inhibition of abl tyrosine kinase
155,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435514,Active,binding constant for abl1 m351t kinase domain
149,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256668,Active,average binding constant for abl1 h396p nanot active at 10 um
147,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256666,Active,average binding constant for abl1 q252h nanot active at 10 um
156,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435515,Active,binding constant for abl1 q252h kinase domain
181,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1308928,Active,inhibition of abl  unknown origin incubated for 1 hr by spectrophotometric analysis
165,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624982,Active,binding constant for abl1 f317l  phosphorylated kinase domain
168,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624985,Active,binding constant for abl1 m351t  phosphorylated kinase domain
151,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256670,Active,average binding constant for abl1 t315i nanot active at 10 um
184,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1481070,Active,inhibition of human abl1 using eaiyaapfakkk as substrate in presence of [gamma 32p]atp
183,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1394735,Active,inhibition of recombinant human abl expressed in insect cells using ulight tk peptide as substrate after 60 mins by lance method
171,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624988,Active,binding constant for abl1 t315i  non phosphorylated kinase domain
153,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,350250,Active,inhibition of abl1
152,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256671,Active,average binding constant for abl1 y253f nanot active at 10 um
172,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624989,Active,binding constant for abl1 t315i  phosphorylated kinase domain
173,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624990,Active,binding constant for abl1 y253f  phosphorylated kinase domain
174,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624991,Active,binding constant for abl1 non phosphorylated kinase domain
175,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624992,Active,binding constant for abl1 phosphorylated kinase domain
176,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,629262,Active,inhibition of abl1
177,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1069558,Active,inhibition of abl  unknown origin after 30 mins
178,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1236888,Active,inhibition of bcr abl1  unknown origin assessed as atp remaining by kinase glo luminescent kinase assay
179,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1236888,Active,inhibition of bcr abl1  unknown origin assessed as atp remaining by kinase glo luminescent kinase assay
180,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1300795,Active,inhibition of abl  unknown origin by mobility shift assay
143,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,228824,Active,inhibition of abl tyrosine kinase
169,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624986,Active,binding constant for abl1 q252h  non phosphorylated kinase domain
170,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624987,Active,binding constant for abl1 q252h  phosphorylated kinase domain
101,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL50,31746,Active,cytotoxic effect on v abl transformed murine ann 1 cells
154,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435146,Active,binding constant for abl1 h396p kinase domain
150,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256669,Active,average binding constant for abl1 m351t nanot active at 10 um
372,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3622828,1251066,Active,inhibition of jak1  unknown origin using 87 um of atp and tyr6 peptide by z' lyte kinase assay
132,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675685,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
356,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL553,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um
131,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675685,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
27,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL428690,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um
73,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL31965,1117354,Active,human jak2 kinase inhibition screen
72,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL31965,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um
270,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675694,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
269,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675694,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
113,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1081484,465242,Active,antiproliferative activity against human set2 cells harboring jak2 v617f mutant after 72 hrs by calorimetry
35,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1725279,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um
363,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3651005,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w
76,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1336,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um
266,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596566,Active,inhibition of human jak2
263,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596364,Active,free drug level in plasma of ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 10 mg/kg po after 6 hrs
310,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3779913,1287924,Active,inhibition of jak2  unknown origin 
262,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596359,Active,inhibition of stat5 phosphorylation in ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 2 5 mg/kg po upto 2 hrs
261,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596357,Active,inhibition of stat5 phosphorylation in ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 5 mg/kg po upto 2 hrs
260,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596355,Active,inhibition of stat5 phosphorylation in ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 10 mg/kg po upto 2 hrs
91,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3746463,1267685,Inactive,inhibition of jak2 in human hel 92 1 7 cells assessed as reduction in stat5 phosphorylation after 2 hrs by western blot analysis
264,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596562,Active,inhibition of jak2 after 60 min
88,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3814195,1306231,Active,inhibition of jak2  unknown origin using tyrosine 6 peptide as substrate by z' lyte assay
265,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596564,Active,inhibition of tel fused jak2 induced proliferation of mouse ba/f3 cells
47,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL460472,662115,Active,inhibition of jak2
112,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1081484,465238,Active,inhibition of gst tagged jak2 assessed as inhibition of biotinylated jak3tide peptide phosphorylation after 60 mins by caliper mobility shift assay
311,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3779913,1287932,Active,inhibition of jak2 in human cd34+ cells assessed as inhibition of epo mediated cell proliferation
334,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
343,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
345,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
335,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
344,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
346,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
333,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
358,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3924451,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
93,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
374,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
373,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
212,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3956651,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
213,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3956651,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
397,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4108322,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
396,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4108322,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
138,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
139,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
392,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
391,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
191,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
92,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
190,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
390,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
140,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
28,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3779913,1287925,Active,inhibition of jak3  unknown origin 
251,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917134,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
252,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917134,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
271,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4115248,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
287,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3926748,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
288,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3926748,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
289,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3926748,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
375,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
94,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
189,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
357,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3924451,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
290,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL3952373,1322599,Active,inhibition of human src by time resolved fluorescence or time resolved fluorescence assay
116,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL103667,256676,Inactive,average binding constant for src nanot active at 10 um
386,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1725279,256676,Inactive,average binding constant for src nanot active at 10 um
387,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1725279,588354,Inactive,luminescence based cell based primary high throughput screening assay to identify inhibitors of the steroid receptor coactivator 1  src1 ncoa1 
117,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL103667,636416,Active,inhibition of c src
281,CHEMBL2599,Tyrosine-protein kinase SYK,CHEMBL428690,256647,Inactive,average binding constant for syk nanot active at 10 um
134,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
135,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
136,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
22,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3288854,1155232,Active,binding affinity to flt3  unknown origin 
23,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3288854,1440304,Active,antiproliferative activity against human mv4 11 cells harboring flt3 itd mutant after 72 hrs by mts assay
280,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
276,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
277,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
278,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
279,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
137,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
133,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
141,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL204727,263662,Active,inhibitory activity against vegfr2
122,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3941174,1340079,Active,inhibition of vegfr2  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay
348,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205405,263662,Active,inhibitory activity against vegfr2
121,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3941174,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
208,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205893,263662,Active,inhibitory activity against vegfr2
126,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL119385,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
211,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3986135,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay
197,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL428690,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
219,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
220,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,414724,Active,inhibition of vegfr2 by liquid scintillation counting
221,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,1444933,Active,inhibition of vegfr2  unknown origin using fam labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of atp by mobility shift assay
223,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL383299,263662,Active,inhibitory activity against vegfr2
193,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205108,263662,Active,inhibitory activity against vegfr2
192,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL91829,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
187,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL31965,1117353,Active,human kdr kinase inhibition screen
186,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL31965,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
185,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL209704,268025,Active,inhibition of vegfr2
255,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL396107,306347,Active,inhibition of human vegfr2 by htrf method
110,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL378299,268025,Active,inhibition of vegfr2
272,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247252,306347,Active,inhibition of human vegfr2 by htrf method
99,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL380372,268025,Active,inhibition of vegfr2
98,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL204985,263662,Active,inhibitory activity against vegfr2
295,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247790,306347,Active,inhibition of human vegfr2 by htrf method
298,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL377230,268025,Active,inhibition of vegfr2
316,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL295528,89312,Active,inhibition of human vegf receptor 2  kdr kinase 
317,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL391184,306347,Active,inhibition of human vegfr2 by htrf method
33,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247228,306347,Active,inhibition of human vegfr2 by htrf method
87,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205406,263662,Active,inhibitory activity against vegfr2
